Insmed (NASDAQ:INSM) Upgraded at Rothschild Redb

Rothschild Redb upgraded shares of Insmed (NASDAQ:INSM) to a strong-buy rating in a research report sent to investors on Thursday,Zacks.com reports.

INSM has been the topic of a number of other research reports. TD Cowen boosted their price target on Insmed from $223.00 to $231.00 and gave the company a “buy” rating in a report on Thursday, November 20th. Guggenheim upped their price target on shares of Insmed from $125.00 to $172.00 and gave the stock a “buy” rating in a research note on Monday, September 8th. JPMorgan Chase & Co. boosted their target price on Insmed from $111.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 20th. Bank of America raised their price target on shares of Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a report on Monday, October 27th. Finally, Wells Fargo & Company boosted their price target on Insmed from $171.00 to $217.00 and gave the company an “overweight” rating in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $187.89.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $204.00 on Thursday. The stock’s 50-day moving average is $180.50 and its 200 day moving average is $134.95. The stock has a market cap of $43.51 billion, a price-to-earnings ratio of -32.96 and a beta of 1.01. Insmed has a 1-year low of $60.40 and a 1-year high of $212.75. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. Insmed’s revenue for the quarter was up 52.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.27) EPS. On average, sell-side analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity

In other news, Director Leo Lee sold 75,000 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the completion of the sale, the director owned 54,677 shares in the company, valued at approximately $10,711,224.30. This represents a 57.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Elizabeth M. Anderson sold 5,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $204.58, for a total transaction of $1,022,900.00. Following the transaction, the director owned 58,729 shares in the company, valued at approximately $12,014,778.82. This trade represents a 7.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 233,650 shares of company stock worth $41,063,785 in the last three months. Corporate insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several hedge funds have recently made changes to their positions in the company. CIBC Private Wealth Group LLC grew its stake in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the last quarter. Kingsview Wealth Management LLC boosted its position in Insmed by 2.7% in the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 60 shares during the last quarter. Choreo LLC increased its holdings in Insmed by 2.9% in the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 65 shares during the period. Spire Wealth Management increased its holdings in Insmed by 11.5% in the 3rd quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 80 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its position in Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 81 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.